PET/CT Quantitative Assessment of Myocardial Blood Flow Changes in Oncologic Patients Receiving Checkpoint Inhibitor Therapy

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

6 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-08-14

Study Completion Date

2022-05-19

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Researchers are trying to determine the side effects on the heart from immune checkpoint inhibitor (ICI) treatment in patients with cancer.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of Value of Cardiac PET Scans With or Without CT Angiography and/or Measurement of Coronary Flow Reserve

NCT00669968

Chest Pain Coronary Artery Disease

COMPLETED

Role of Multi-modality Imaging in the Assessment of Chemotherapy Related Cardiac Dysfunction Among Cancer Patients

NCT06206395

2D Speckle Tracking Echocardiography Breast Cancer Cardiac Magnetic Resonance

NOT_YET_RECRUITING

Initial Human Validation of Simultaneous Dual-Tracer Cardiac PET Imaging

NCT02003456

Ischemic Heart Disease Myocardial Infarction

COMPLETED EARLY_PHASE1

MyoStrain CMR for the Detection of Cardiotoxicity

NCT03543228

Cardiotoxicity Heart Failure Chemotherapeutic Toxicity

COMPLETED

Cadmium-zinc-telluride (CZT) Imaging of Myocardial Blood Flow (MBF) (SPECT MBF)

NCT02280941

Coronary Heart Disease

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Checkpoint Inhibitor (ICI)

Subjects diagnosed with cancer and will be receiving immune checkpoint inhibitors as treatment standard of care will have a PET/CT scan before and after therapy. PET/CT scan is done for study purposes only.

Group Type OTHER

PET/CT

Intervention Type DIAGNOSTIC_TEST

Positron emission tomography-computed tomography is an image test that helps show detail about how tissues and organs are functioning.

radioactive drug (tracer)

Intervention Type DRUG

A radioactive drug (tracer) is used in the PET scan.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PET/CT

Positron emission tomography-computed tomography is an image test that helps show detail about how tissues and organs are functioning.

Intervention Type DIAGNOSTIC_TEST

radioactive drug (tracer)

A radioactive drug (tracer) is used in the PET scan.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* First time administration of ICI
* Willing and able to return in 4-6 weeks for follow-up study
* Patients with previous heart conditions included (while this may impact MFR the delta MFR is what we are assessing)